Keyword: Olumiant (baricitinib)
ICER is still concerned about high prices of next-generation RA drugs—a stance that's not going over well among RA drugmakers and patient groups.
ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.
Eli Lilly and Incyte's Olumiant has run up against safety hurdles in the past. But can they stop the drugmakers from adding another indication?
JAK drugs have run into safety issues, and if the label for AbbVie's Rinvoq is any indication, the FDA now believes those the issues are class-wide.
Pfizer’s Xeljanz has had its share of hiccups after pulmonary embolism fears derailed the drug’s high-dose hopes in RA. Could new data help the cause?
Eli Lilly and Incyte’s Olumiant path has been a precarious one, with the FDA repeatedly knocking the drug’s larger dose. Can new safety data help?
Lilly CEO David Ricks, in his second year on the job, hauled in a pay package larger than those of a few of his big pharma peers.
Pfizer has run into safety issues with Xeljanz. But whether the issues belong to the drug—rather than to its burgeoning class—remains to be seen.
Generic competition is weighing on Cialis, but luckily for Lilly, several new drugs are on the upswing, including top performers Trulicity and Taltz.